Shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA – Get Free Report) traded down 11.9% during trading on Wednesday. The company traded as low as $0.7512 and last traded at $0.8217. 495,551 shares were traded during mid-day trading, a decline of 21% from the average daily volume of 629,433 shares. The stock had previously closed at $0.9323.
Wall Street Analyst Weigh In
Separately, Weiss Ratings raised Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $8.00.
View Our Latest Stock Analysis on Estrella Immunopharma
Estrella Immunopharma Price Performance
The company has a 50-day simple moving average of $0.58 and a 200 day simple moving average of $0.98.
Estrella Immunopharma (NASDAQ:ESLA – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.04. As a group, sell-side analysts forecast that Estrella Immunopharma, Inc. will post -0.25 earnings per share for the current year.
Institutional Investors Weigh In On Estrella Immunopharma
A hedge fund recently bought a new stake in Estrella Immunopharma stock. BlackRock Inc. bought a new stake in shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 52,033 shares of the company’s stock, valued at approximately $54,000. BlackRock Inc. owned about 0.12% of Estrella Immunopharma at the end of the most recent quarter. 0.35% of the stock is owned by hedge funds and other institutional investors.
About Estrella Immunopharma
Estrella Immunopharma, Inc (NASDAQ: ESLA) is a clinical-stage biopharmaceutical company focused on developing cellular immunotherapies for cancer and other serious diseases. The company’s work centers on genetically engineered T-cell therapies designed to recognize and destroy target cells.
Estrella’s lead program is EB103, a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy being developed for the treatment of certain B-cell malignancies. The company has described EB103 as being based on its ARTEMIS platform, which is intended to support targeted immune-cell activity while addressing some limitations associated with conventional CAR-T therapies.
Estrella became a publicly traded company through a business combination with TradeUP Global Corporation.
Featured Stories
- Five stocks we like better than Estrella Immunopharma
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Estrella Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Estrella Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
